NNVC — NanoViricides, Share News
0.000.00%
Brief: Nanoviricides Says Data Shows Pan-Coronavirus Nanopviricide Drug Candidate NV-Cov-2-R Minimizes Loss Of Remdesivir To Bodily Metabolism
NanoViricides rises on COVID-19 drug licensing deal
Brief: NanoViricides Completes Licensing For Coronavirus Field Including COVID-19 Drug Development
AMEX RESUMED NANOVIRICIDES
AMEX HALT ADDITIONAL INFORMATION LAST 5.110000
AMEX RESUMED NANOVIRICIDES
AMEX HALT ADDITIONAL INFORMATION LAST 5.500000
AMEX HALT EQUIPMENT CHANGEOVER LAST 3.50420
Brief: NanoViricides Files For Non-Timely 10-K With U.S. SEC
NanoViricides Inc: Rises on selecting COVID-19 drug candidate
Brief: NanoViricides Says Nominated Clinical Drug Candidate For Treatment Of COVID-19
RCS - NanoViricides, Inc. - NanoViricides in BRileyFBR InfectiousDiseaseSummit
Brief: Altium Capital Management LP Reports 7.2% Passive Stake In Nanoviricides
RCS - NanoViricides, Inc. - NanoViricides Raises $11.5M-Underwritten Offering
RCS - NanoViricides, Inc. - NanoViricides Prices $10million Public Offering
U.S. STOCKS ON THE MOVE-Boxlight Corp, Aqua Metals, Lovesac, Macy's
NanoViricides Inc: Jumps on MoU for COVID-19 drug development license
Brief: Nanoviricides Files For Offering For Sale, Directly To Selected Investors, 1.4 Mln Shares Of Common Stock At $7.30 Per Share
RCS - NanoViricides, Inc. - Strong Effectiveness of NanoViricides Drug